Arcus Capital Partners’s Mustang Bio MBIO Stock Holding History

Arcus Capital Partners’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3	Closed	-$7K	–	119
2019 Q2	$7K	Buy	+3	New	+$8.56K	﹤0.01%	120

Other funds holding MBIO

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Arcus Capital Partners's MBIO Position: Q3 2019 in Review

Arcus Capital Partners sold out of Mustang Bio (MBIO) in Q3 2019, closing a stake of 3 shares — an estimated $7K sold.

Arcus Capital Partners first reported a position in MBIO in Q2 2019 and held it in 1 quarter. The position peaked at $7K in Q2 2019. 55 funds tracked by Wall St. Rank hold MBIO as of Q3 2019.

Arcus Capital Partners reported no remaining Mustang Bio position as of Q3 2019 after selling out during the quarter.
Arcus Capital Partners sold 3 Mustang Bio shares in Q3 2019, an estimated $7K.
Arcus Capital Partners first reported a position in Mustang Bio in Q2 2019 and held it in 1 quarter.
Arcus Capital Partners's Mustang Bio position peaked at $7K in Q2 2019.
55 funds tracked by Wall St. Rank held Mustang Bio as of Q3 2019.

Based on Arcus Capital Partners's 13F filing for Q3 2019, filed 31 Oct 2019.